Quantum Genesis AI Corp. (OTC: QGAI), a technology company focused on artificial intelligence and computational modeling, issued a statement on March 12, 2026, addressing the Caveat Emptor designation placed on its securities by OTC Markets Group, Inc. on February 12, 2026. The designation, which signals potential public interest concerns, has prompted the company to seek clarification and pursue a formal review process.
Since the designation was applied, the company has made several attempts to communicate with OTC Markets to understand the basis for the action. OTC Markets indicated that the designation relates to a “public interest concern,” but has not provided specific details. Quantum Genesis AI has requested additional clarification and intends to continue cooperating to address the matter.
OTC Markets recently informed the company that it may formally request a review of the designation beginning March 13, 2026. Quantum Genesis AI intends to engage with OTC Markets at the earliest opportunity to initiate that review process. “We take this matter seriously and are committed to working constructively with OTC Markets to better understand the basis for the designation,” said Naveen Kulkarni, Chief Executive Officer. “Our objective is to obtain clarity regarding the matter and to take any appropriate steps necessary as we move through the review process.”
The company remains committed to transparency with its shareholders and the broader investment community. It intends to continue cooperating with OTC Markets and will provide updates as additional information becomes available. For more information, visit www.qgaicorp.com and the company’s profile at www.otcmarkets.com/stock/QGAI.
Quantum Genesis AI Corp. is focused on advancing next-generation technologies at the intersection of artificial intelligence, computational modeling, and scientific innovation. The company’s strategy includes leveraging advanced data-driven tools to support research, discovery, and technology development across emerging sectors while maintaining a commitment to transparency and responsible corporate governance.
The Caveat Emptor designation is a significant event for the company, as it may affect investor confidence and the trading of its securities. The designation is used by OTC Markets to warn investors that there may be a public interest concern associated with a company, such as a lack of current financial information, an investigation by a regulatory authority, or other issues. For Quantum Genesis AI, the designation appears to stem from undisclosed concerns that the company is now working to resolve.
The company’s proactive approach in seeking a review and cooperating with OTC Markets could help mitigate the impact of the designation. However, the outcome remains uncertain, and the company has not provided a timeline for resolution. Investors are advised to monitor updates from the company and OTC Markets.
